Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia

Date

14 Sep 2024

Session

Poster session 10

Topics

Clinical Research

Tumour Site

Acute Myeloid Leukaemia

Presenters

Guidantonio Malagoli Tagliazucchi

Citation

Annals of Oncology (2024) 35 (suppl_2): S762-S774. 10.1016/annonc/annonc1599

Authors

W. Gong1, M. Ghildiyal2, M. Chavez3, K. Nobuta4, E. Sayyari5, S. Truong5, T. Vang2, M. Yaylaoglu2, G. Kim2, Q. Bui2, D. Spencer6, S. Kim3, J. Bernd7, E. De Feo7, S. Comer7

Author affiliations

  • 1 Ils R&d Sw Dev And Bi/enablement Department, Illumina, Inc., 94404 - Foster City/US
  • 2 Ils R&d Lab Solutions Department, Illumina, Inc., 92122 - San Diego/US
  • 3 Ils R&d Sw Dev And Bi/enablement Department, Illumina, Inc., 92122 - San Diego/US
  • 4 Ils R&d Sw Dev And Bi/enablement Dept, Illumina, Inc., 92122 - San Diego/US
  • 5 Bioinformatics Department, Illumina, Inc., 92122 - San Diego/US
  • 6 John T. Milliken Department Of Medicine, Division Of Oncology, Washington University in St. Louis, 63110 - St. Louis/US
  • 7 Ils Lab Ops Admin Department, Illumina, Inc., 92122 - San Diego/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1203P

Background

Acute myeloid leukemia (AML) is the most common leukemia in adults and current methods rely on cytogenic and molecular profiling for AML classification. Recent advances have demonstrated that next generation sequencing (NGS) may improve prognostic prediction and risk stratification of AML patients. A tumour-only high coverage whole genome sequencing (WGS) method was developed to assess the analytical performance (limit of detection (LoD)), sensitivity, specificity and reproducibility) in identifying somatic small variants, structural variants (SV) and copy number alterations (CNA) specific to AML.

Methods

Seracare® myeloid panel, NOMO1, Kasumi1, HCC1187 and 53 AML clinical specimens were used to assess analytical performance. Extracted genomic DNA (∼350ng) from contrived specimens, cell lines, mononuclear cells from whole blood or bone marrow aspirate were manually processed with Illumina DNA PCR Free Prep and sequenced at 4 plex on S4 flowcells using NovaSeq™ 6000. The sequence data was analysed by DRAGEN™ Somatic v4.2 with a custom virtual 156 AML specific gene panel variant classification algorithm.

Results

The samples were sequenced at an average of ∼220X which yielded high analytical sensitivity, accuracy and reproducibility of the specimens evaluated in this study. Although the target sequence was ∼220X, samples were in silico down sampled to 140X to establish the following performance specifications. LoD was established for small variant (SNVs and indels) and SV to be 5% and 7.3%, respectively. CNA were detected with copy number fold change of 1.09 and 0.87 for duplication and deletion events, respectively. Further, loss of heterozygosity was detected with purity of 17%. Overall, we observed accuracy >95% across clinical samples with analytical sensitivities >95%, >99% and >95% for small variants, SV and CNA, respectively and analytical specificity of >99.9%.

Conclusions

We have developed a tumour only WGS method for genomic profiling of AML patients with a turn around time of 5 days. The analytical performance of this tumour only WGS approach indicates high accuracy in identifying variants indicative for AML. In addition, the high sequence depth provides improved analytical sensitivity compared to other genome sequencing or cytogenetic methods.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Illumina.

Funding

Illumina.

Disclosure

G. Malagoli Tagliazucchi, W. Gong, M. Ghildiyal, M. Chavez, K. Nobuta, E. Sayyari, S. Truong, T. Vang, G. Kim, Q. Bui, S. Kim, J. Bernd, E. De Feo, S. Comer: Financial Interests, Institutional, Full or part-time Employment: Illumina. M. Yaylaoglu: Financial Interests, Personal and Institutional, Full or part-time Employment: Illumina. D. Spencer: Financial Interests, Institutional, Financially compensated role: Washington University in St. Louis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.